Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155074 | 0.90 | TSHR (0.36) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3929628 | 0.80 | CYP3A4 (0.51) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL9986194 | 0.80 | CYP3A4 (0.51) | CA2TSHRCYP3A4ATMTDP1 | |
| SCHEMBL10377995 | 0.79 | CA2 (0.35) | CA2CA1TSHRCYP3A4ATM | |
| SCHEMBL185251 | 0.78 | MAPT (0.42) | CA2CA1MAPTALDH1A1ZDHHC7 | |
| SCHEMBL7959392 | 0.78 | NAAA (0.43) | CA2CA1TSHRCYP3A4MAPT | |
| SCHEMBL7712595 | 0.78 | TSHR (0.45) | CA2CA1TSHRCYP3A4ATM | |
| SCHEMBL9737113 | 0.78 | FAAH (0.51) | CA1L3MBTL1MAPTALDH1A1ZDHHC7 | |
| SCHEMBL9161765 | 0.77 | MAPT (0.44) | CA2CA1TSHRATMMAPT | |
| SCHEMBL6388508 | 0.77 | NAAA (0.46) | CA2CA1TSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | CA2 1552/4885CA1 4120/4885TSHR 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.